Reactive Biosciences

Executive Summary

Reactive Biosciences is a private, San Diego-based biotechnology company founded in 2019 that leverages the unique chemical properties of boron to develop small molecule therapeutics targeting historically undruggable disease pathways. By exploiting boron's ability to form reversible covalent bonds, the company aims to address challenging targets that have eluded traditional drug discovery approaches. Reactive Biosciences is led by a team with deep expertise in boron chemistry and drug development, focusing on areas with high unmet medical need. The company's platform is designed to unlock new therapeutic possibilities in oncology, inflammation, and other serious diseases, with the goal of changing the course of disease and improving patients' lives. While still in early preclinical stages, Reactive Biosciences has the potential to differentiate itself through its boron-centric platform that offers novel binding mechanisms and selectivity. However, as a private company with no disclosed pipeline or financial details, the venture remains high-risk and requires significant validation through preclinical studies and eventual clinical trials. The company's success will depend on advancing its lead programs to candidate nomination, securing funding, and generating compelling in vivo proof-of-concept data. If successful, Reactive Biosciences could pioneer a new class of boron-based drugs, but near-term visibility is limited.

Upcoming Catalysts (preview)

• TBDSeries A Financing Round70% success
• Q4 2026Preclinical Lead Candidate Nomination60% success
• TBDResearch Collaboration or Licensing Deal40% success